EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

cIMPACT-NOW update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas

Felix Sahm iD, Kenneth D Aldape, Priscilla K Brastianos iD, Daniel J Brat, Sonika Dahiya iD, Andreas von Deimling iD, Caterina Giannini iD, Mark R Gilbert, David N Louis, David R Raleigh, Guido Reifenberger, Sandro Santagata und 4 weitere

Neuro-Oncology · 10.02.2025 · 27 (2) · 319-330

DOI: 10.1093/neuonc/noae170 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Neuro-Oncology, online erschienen am 30.08.2024. Verfasst von Felix Sahm und 15 weiteren Autor:innen. Beteiligte Einrichtung: CCU Neuropathology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany. Hauptthemen laut MEDLINE: Meningioma, Meningeal Neoplasms, Biomarkers, Tumor, DNA Methylation. Die Arbeit wurde bisher 146-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Meningiomas are the most frequent primary intracranial tumors. Hence, they constitute a major share of diagnostic specimens in neuropathology practice. The 2021 WHO Classification of Central Nervous System Tumors (“CNS5”) has introduced the first molecular grading parameters for meningioma with oncogenic variants in the TERT promoter and homozygous deletion of CDKN2A/B as markers for CNS WHO grade 3. However, after the publication of the new classification volume, clarifications were requested, not only on novel but also on long-standing questions in meningioma grading that were beyond the scope of the WHO “blue book.” In addition, more recent research into possible new molecular grading parameters could not yet be implemented in the 2021 classification but constitutes a compelling body of literature. Hence, the consortium to inform molecular and practical approaches to CNS tumor taxonomy-not official WHO (cIMPACT-NOW) Steering Committee convened a working group to provide such clarification and assess the evidence of possible novel molecular criteria. As a result, this cIMPACT-NOW update provides guidance for more standardized morphological evaluation and interpretation, most prominently pertaining to brain invasion, identifies scenarios in which advanced molecular testing is recommended, proposes to assign CNS WHO grade 2 for cases with CNS WHO grade 1 morphology but chromosomal arm 1p deletion in combination with 22q deletion and/or NF2 oncogenic variants, and discusses areas in which the current evidence is not yet sufficient to result in new recommendations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MeningiomaMeningeal NeoplasmsBiomarkers, TumorDNA MethylationPractice Guidelines as TopicHumansWorld Health OrganizationNeoplasm Grading

Stichwörter der Autor:innen

WHO classificationcIMPACT-NOWclassificationgradingmeningiomamolecular neuropathology

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • CCU Neuropathology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany.
  • Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Divisions of Hematology/Oncology and Neuro-Oncology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  • Division of Neuropathology, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.

ORCID-Profile: Felix Sahm, Priscilla K Brastianos, Sonika Dahiya, Andreas von Deimling, Caterina Giannini, Gelareh Zadeh

Förderung

  • NCI NIH HHS

Zitieren

APA

Sahm, F., Aldape, K. D., Brastianos, P. K., Brat, D. J., Dahiya, S., von Deimling, A., Giannini, C., Gilbert, M. R., Louis, D. N., Raleigh, D. R., Reifenberger, G., Santagata, S., Sarkar, C., Zadeh, G., Wesseling, P., & Perry, A. (2025). cIMPACT-NOW update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas. Neuro-Oncology, 27(2), 319-330. https://doi.org/10.1093/neuonc/noae170

Vancouver

Sahm F, Aldape KD, Brastianos PK, Brat DJ, Dahiya S, von Deimling A, et al. cIMPACT-NOW update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas. Neuro-Oncology. 2025;27(2):319-330. doi:10.1093/neuonc/noae170

BibTeX
@article{Sahm2025,
  author = {Sahm, Felix and Aldape, Kenneth D and Brastianos, Priscilla K and Brat, Daniel J and Dahiya, Sonika and von Deimling, Andreas and Giannini, Caterina and Gilbert, Mark R and Louis, David N and Raleigh, David R and Reifenberger, Guido and Santagata, Sandro and Sarkar, Chitra and Zadeh, Gelareh and Wesseling, Pieter and Perry, Arie},
  title = {cIMPACT-NOW update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas},
  journal = {Neuro-Oncology},
  year = {2025},
  volume = {27},
  number = {2},
  pages = {319--330},
  doi = {10.1093/neuonc/noae170}
}
Kostenlos starten →